Eli Lilly | LLY - Current Liabilities


Eli Lilly reported $36.63B in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
AbbVie USD 42.1B 1.19B Mar/2026
Abbott USD 18.38B 1.88B Mar/2026
ALKERMES USD 599.5M 56.06M Mar/2026
Amgen USD 24.96B 534M Mar/2026
AstraZeneca USD 32.57B 1.95B Mar/2026
Baxter International USD 3.69B 723M Mar/2026
Biogen USD 3B 350.5M Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Coherus Biosciences USD 140.39M 231.91M Dec/2025
Drreddys Laboratories INR 1.76B 62.5M Dec/2025
Eli Lilly USD 36.63B 1.41B Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
Glaxosmithkline GBP 28.82B 144.79M Dec/2025
J&J USD 57.72B 3.59B Mar/2026
Medtronic USD 9.5B 440M Dec/2025
Merck USD 26.94B 1.38B Mar/2026
Neurocrine Biosciences USD 831.7M 88.3M Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Novartis USD 27.28B 4.72B Dec/2025
Novo Nordisk DKK 225.16B 9.5B Mar/2026
Perrigo USD 997.6M 15.3M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Phibro Animal Health USD 281.87M 500K Mar/2026
Prestige Brands USD 120.92M 18.63M Mar/2026
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Roche Holding CHF 28B 421M Dec/2025
Sanofi EUR 30.01B 1.66B Mar/2026
Sanofi EUR 28.35B 9.32B Dec/2025
United Therapeutics USD 599.1M 38.5M Mar/2026
Zoetis USD 2.05B 182M Mar/2026